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Caspase 8Purpose: It is now well known that evading apoptosis, as a cancer hallmark, can lead to tumour initiation,
progression and metastasis. As a result of genome wide association studies, an initiator protease in this
pathway, caspase 8 (CASP8), has been found to be an important gene regarding breast cancer suscepti-
bility. The alterations of the expression of this gene have been reported in breast cancer cell lines.
Given that in previous studies expression analysis of this gene had only been done in breast cancer cell
lines, in this study we aimed to evaluate the expression of this gene in breast cancer tissues versus adja-
cent normal tissues, using real-time quantitative method.
Methods: Caspase 8 mRNA expression was quantified using comparative RT-qPCR in 27 fresh frozen
breast tumours and 27 adjacent normal tissues. Moreover, relationship between the expression changes
of CASP8 in tumour tissue and various clinical and pathological features were evaluated in an Iranian
population.
Results: The present study showed that expression of CASP8 was significantly reduced in tumour tissues
compared to neighbouring normal tissues (p = .004). CASP8 expression was significantly correlated with
the status of hormone receptors (ER and PR).
Conclusion: To the best of our knowledge, this study is the first report on reduced expression of CASP8 in
breast cancer versus adjacent normal tissues. Our data support previous results obtained from cell lines
and therefore highlights the seminal role of the induction of CASP8 expression, as a novel therapeutic
approach, in order to sensitize tumour cells to apoptotic stimuli.
 2017 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Breast cancer is the most prevalent female malignancy and the
second cause of cancer death in women worldwide [1]. The inci-
dence of breast cancer is increasing in Iran and it is still at thetop of the list of female neoplasms similar to other parts of the
world [2,3]. Different cellular pathways are involved in carcinogen-
esis of cancers, one of which is apoptosis. It is over 16 years that
apoptosis has been known as one of the main pathways in carcino-
genesis. Evading apoptosis, as a cancer hallmark, was first intro-
duced by Hanahan et al. in 2000 as one of the main biological
skills acquired during the multistep development of human
tumours [4]. This pathway can be triggered by a variety of intra-
and extracellular factors during tumour development including
radiation, loss of cell-matrix interaction, hypoxia, DNA damages
and telomere malfunction [5]. Cells that may lack apoptosis can
survive and initiate tumour development or clonal expansion
within the tumour or invade other tissues [6]. Additionally, anti-
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defect in the process of apoptosis can result in treatment failure,
tumour relapse and/or metastasis [7]. Alterations in this cellular
pathway occur due to genetic and epigenetic changes in cancer
cells. Transcriptome is one of the levels in which the results of such
changes can be assessed. Gene expression profiling has changed
the face of breast cancer classification and management. By use
of quantitative reverse transcriptase polymerase chain reaction
(RT-PCR) and cDNA microarray expression technology, tumours
with specific gene expression patterns have been identified. This
has led to the development of a new classification strategy, catego-
rization of breast cancers into molecular subtypes, including lumi-
nal A, luminal B, basal-like, HER-2/neu-overexpressing, claudin low
and finally normal-like breast tumours [8]. The discovery of the
molecular breast cancer subtypes, helped to differentiate groups
of cancers that were morphologically similar but were widely dif-
ferent, especially with respect to response to different therapeutic
strategies [9]. On the other hand, over the last several years, mul-
tiple genome-wide association studies and candidate-gene associ-
ation studies have shown that some common variants of CASP8 -
initiator caspase in apoptosis pathway- are associated with breast
cancer risk. This evidence also shows that some variants of CASP8
may affect its expression. CASP8 – 652 6 N Del (rs3834129) – which
is located in the promoter region of the CASP8 gene – is associated
with decrease in expression of CASP8 mRNA [10–12]. Negative
prognostic impact of this CASP8 polymorphism along with another
SNP of this gene, Asp302His (rs1045485), has been recently shown
in breast cancer [13]. In general, caspases work as conserved cys-
teine endoproteinases and play a crucial role in ‘‘programmed cell
death”. By activation of death receptors, CASP8 initiates apoptosis
process in normal cells. Since signalling via the death receptor
(extrinsic) pathway critically depends on CASP8, the disturbance
of CASP8 function or reduction of its expression may contribute
to human diseases [14]. The alterations in the expression of this
gene have been reported in a variety of tumours and also in breast
cancer cell lines [15–18]. Understanding changes in apoptosis
pathway not only gives clues about the pathogenesis of cancer,
but also can result in finding therapeutic strategies. Since loss of
expression or function of caspase-8 has an obvious effect on the
ability of cancer cells to undergo apoptosis, different strategies
have been studied to upregulate CASP8 expression in order to
restore its function in tumours lacking this essential apoptosis reg-
ulator [19,20]. This fact shows that CASP8 can be a specific thera-
peutic target for different cancers in the near future.
In previous studies, expression analysis of this gene had only
been done in breast cancer cell lines by qualitative methods. Thus,
in this study we aimed to evaluate the expression of this gene in
breast cancer tissues versus adjacent normal tissues, using real-
time quantitative methods. Another goal of this study was to inves-
tigate relationships between expression changes of CASP8 with
other factors such as HER2, HR markers, grade of tumour and other
demographic factors in an Iranian population.Materials and methods
Sample collection
Thirty patients with primary diagnosis of breast cancer were
enrolled in this pilot study. According to our exclusion criteria,
three patients were excluded based on the pathological examina-
tion of tissues which showed no tumour involvement. Twenty-
seven primary breast tumour and normal adjacent tissues were
obtained from patients who had undergone breast surgery at Omid
and Qaem hospitals in Mashhad. All patients had not received pre-
operative chemotherapy. The samples were collected after obtain-ing patients’ written consent following approval by the ethical
committee of Mashhad University of Medical Sciences. The sam-
ples were directly collected in RNAlater Thermo Fisher (Carlsbad,
CA, USA) for immediate isolation of total RNA and stored at -80 C
for later use.
RNA Extraction and cDNA synthesis
Total RNA was extracted using TRIzol Reagent (Ambion, Carls-
bad, CA, USA) according to the manufacturer’s instructions. The
concentrations of isolated RNA samples were read using Nanodrop
at 260 and 280 nm. Analysis of RNA by agarose gel electrophoresis
showed sharp 18 s and 28 s rRNA bands that were indicative of
intact RNA. Reverse transcription of the RNA (1 lg) into cDNA
was performed using RevertAid First Strand cDNA Synthesis kit
(Fermentas, Burlington, USA) based on the manufacturer’s proto-
cols. In order to confirm the cDNA synthesis, using GAPDH primers,
PCR reaction was initiated at 94 C for 3 min and amplified during
35 cycles at 94 C for 30 s, 58 C for 30 s and 72 C for 45 s and fol-
lowed by a final extension step at 72 C for 5 min according to the
manufacturer’s instructions. Finally, the PCR products were visual-
ized by gel electrophoresis on a 2% agarose gel.
Real-Time Polymerase Chain Reaction (PCR)
The CASP8 gene expression levels in tumour and adjacent nor-
mal tissues were measured by quantitative real time PCR in Roche
LightCycler 96 instrument using SYBR Premix Ex Taq II (TAKARA,
Japan). The total 15 ll reaction volume contained 7.5 ll SYBR Pre-
mix, 1.5 cDNA, 0.3 lM of each primers and 4 ll ddH2O. Thermal
cycling consisted of an initial denaturation step 95 C for 5 min fol-
lowed by an amplification program repeated for 40 cycles. The
amplification program was 95 C for 15 s, 60 C for 30 s and 72 C
for 30 s with a single fluorescence acquisition at the end of the
elongation step. ACTB gene was used as internal control. All qPCR
reactions were done in triplicate. The primer sequences for real
time PCR are shown in Table 1. All primers were selected from
the cited articles [21,22].
Statistical analysis
To assess distribution of DCT, Shapiro-Wilk normality test was
done in both healthy and tumour groups. Since the test results
showed not normally distributed data, ‘‘Wilcoxon Signed Rank”
test was used to compare theDCT in the two paired groups (tissues
of tumour and normal tissues are for the same patients). Also, for
testing the significance of changes in the CASP8 expression, Wil-
coxon Signed Rank Test was used. Associations between CASP8
expression and patients’ clinicopathological features, including
age, menstrual status, family history of breast cancer, tumour size
and grade, lymph node metastasis (LNM), status of HR, and HER-2,
were assessed by Fisher’s exact test. The power of this study was
calculated based on the current sample size (27 in each group) as
well as difference between delta Ct and related standard deviation
in two groups, considering a level at 0.05. The statistical analysis
was done using by SPSS v22.0 (IBM, Chicago, IL)Results
Patients’ characteristics
Analyses for the expression of CASP8 were performed for
tumour and matched normal tissue of 27 patients with sporadic
breast cancer. The mean age of the patients was 48.15 years old.
A total of 16 patients (59.2%) were premenopausal, and 11 patients
Table 1
Real-time PCR primers.
Gene Sequence (50->30) Length Tm GC% Length of product
CASP8 Primer Forward CCAGAGACTCCAGGAAAAGAGA 22 58.83 50 185
CASP8 Primer Reverse GATAGAGCATGACCCTGTAGGC 22 60.03 54.5
b-Actin Primer Forward TCCCTGGAGAAGAGCTACGA 20 59.38 55 194
b-Actin Primer Reverse AGCACTGTGTTGGCGTACAG 20 60.88 55
Table 3
Summary of the Pathological Features of Breast Cancer Patients.
Immunohistochemical characteristics No. of cases
HR Status
HR + 13 (48.2)
HR - 5 (18.5)
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involvement while 17 patients (63%) had normal report. All
patients participating in this research had invasive ductal carci-
noma (IDC) according to the pathology reports. The majority of
patients (18, 66.7%) were classified as grade II, 3 (11.1%) grade I




HER-2 equivocal 5 (18.5)
Not available 9 (33.3)
Ki67 status
Ki67 + 18 (66.7)
Ki67– 0
Not available 9 (33.3)
Tumor grade
Grade I 3 (11.1)
Grade II 18 (66.7)
Grade III 6 (22.2)
Lymph node involvement
Positive 10 (37)
Negative 17 (63)Real-time PCR results
The present study showed that expression of CASP8 was
reduced in tumour tissues compared to neighbouring normal tis-
sues in our patients. The Ct mean in tumour group was 9.3 (SD =
1.66) and in normal group was 7.83 (SD = 2.44). Based on Wicoxon
test, the DCt difference of CASP8 between the tumour group and
the normal group was significant (p = .004) indicating that expres-
sion of this gene in cancerous tissues was significantly lower than
that in adjacent normal tissues. However, comparison of the
results based on fold change in all specimens showed a 44% non-
significant reduction (p = .06) in expression of CASP8 in tumour tis-
sue. CASP8 was down regulated in 19 of 27 tumours while in 8
tumours this gene was upregulated (Table 4).Table 2
Demographic characteristics of patients.












Family history of breast cancer
Positive 5 (18.5)
Negative 18 (66.7)




Not available 4 (14.8)
















Not available 7 (26)
Table 4





Mean of CASP8 DDCT
(DCTTumour  DCT Normal)








19 (70) 2.43 0.57
Unchanged 0 (0) – –Relationship between expression of CASP8 and clinicopathological
features
We analyzed the associations between levels of CASP8 expres-
sion and a series of clinicopathological characteristics, including
age, menstrual status, family history of breast cancer, BMI, OCP
consumption, tumour size, LNM and the status of HR, and HER-2,
in breast cancer patients (Table 5). We detected downregulated
CASP8 expression more in HR positive tumour; 84% of HR positive
tumours were clustered in downregulated group while this pro-
portion was only 20% for HR negative tumours (p = .022). Other
factors were not significantly associated with CASP8 expression,
for instance CASP8 down regulation was observed more in patients
with negative family history of breast cancer (13 of 18 patients,
72.2%) than patients who had positive family history of breast can-
cer (2 of 5 patients, 40%) but this difference was not statistically
significant (P = .297).Discussion
The aim of this study was firstly to evaluate the expression of
CASP8 in breast cancer tissue compared to normal tissue of the
same patients; and secondly, we aimed to investigate relationships
Table 5
Assiciation between CASP8 expression and clinicopathological features.
Characteristics Down regulation Up regulation p-Value
Age
<50 10 (66.7) 5 (33.3)
50 9 (75) 3 (25) 0.696
Menstrual status
Menopause 8 (72.7) 3 (27.3) 1.000
Non-menopause 11 (69) 5 (31)
Family history of breast cancer
Positive 2 (40) 3 (60) 0.297
Negative 13 (72.2) 5 (27.8)
BMI
20 2 (66.7) 1 (33.3) 0.368
20–25 3 (100) 0 (0)
25 8 (57) 6 (43)
OCP consumption
Yes 5 (71.5) 2 (28.5) 1.000
No 10 (62.5) 6 (37.5)
Tumor size
2 cm 9 (82) 2 (18) 0.765
2–5 cm 5 (71.5) 2 (28.5)
5cm 3 (60) 2 (40)
LNM
Positive 8 (80) 2 (20) 0.666
Negative 11 (64.7) 6 (35.3)
Tumor grade
I 2 (66.7) 1 (33.3) 0.970
II 13 (72.2) 5 (27.8)
III 4 (66.7) 2 (33.3)
HR Status
Positive 11 (84.6) 2 (15.4) 0.022*
Negative 1 (20) 4 (80)
HER-2 status
Positive 3 (75) 1 (25) 0.894
Negative 6 (66.7) 3 (33.3)
Equivocal 3 (60) 2 (40)
* significant correlation.
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biochemical markers, clinical specificities and demographic deter-
minants. As it was expected based on CASP80smechanism of action,
the main result of this study has shown a significant reduction (p =
.004) in the expression of CASP8 in tumour tissue, compared with
normal neighbouring tissues. On the other hand, the result of fold
change calculations showed a reduction of 44% in the expression of
CASP8 in tumour tissues, though this difference was not statisti-
cally significant (p = .06).
The role of apoptotic defects in formation of malignancies, their
progression and invasion is well documented today [6]. CASP8 is
one of the potential genes the inactivation of which can disrupt
apoptosis. This protease is one of the main initiators of pro-
grammed cell death [14]. As an external validity, other studies on
different types of human cancer have shown significant reduction
of CASP8 expression in tumour cells, which can be caused by a vari-
ety of genetic, epigenetic or post-translational mechanisms. These
changes were previously reported, particularly in breast cancer cell
lines [15,17,18]. It has also been recently shown that CASP8 plays a
role in the suppression of oncogenic transformation, regardless of
its role in apoptosis. The absence of caspase-8 can facilitate other
oncogenic mutations and/or accumulation of spontaneous onco-
genic changes. For example, there is evidence showing that phos-
phorylation of tyrosine 380 in CASP8 can result in increase of cell
migration. This report suggests that the absence of caspase-8
may lead not only to decreased apoptosis, but also to enhanced
motility of affected cells [23,24]. Furthermore, other studies show
that a reduction in expression of CASP8 is associated with MYCN
oncogene amplification and increase of its related protein [25].All these evidences emphasize on CASP8 involvement in
carcinogenesis.
According to results of recent genome wide association studies,
finding common variants in this gene which are associated with
breast cancer risk brought CASP8 name one more time to the atten-
tion. Expression of CASP8 can be dysregulated by some of its poly-
morphisms, an example of such gene variation is 652 6Ndel which
shows a reduction in expression and also has a negative impact on
prognosis of breast cancer patients [23,26]. Previous studies also
found association between expression of CASP8 and stage of
tumour or prognosis of the disease. For instance, lack of CASP8
expression in medulloblastoma is correlated with undesirable
prognosis. Also, a significant relationship between the decrease
in CASP8 expression and the stage of head and neck squamous cell
carcinoma (HNSCC) has been reported [27,28]. Patient follow up in
the future can help us find out about the effect of CASP8 alterations
on the survival rate of our patients and their prognosis.
Another aim of this study was to investigate the relationship of
CASP8 expression level with Her2 and hormone receptors expres-
sion status and other patients’ characteristics. Based on these anal-
yses, we found significant relationships between CASP8 expression
and status of HR in breast cancer patients.
One of the main points of this study is the reasonable statistical
power (>80%) which was calculated based on the difference
between delta Ct means (1.48) and related standard deviation
(1.7) in both groups.
To the best of our knowledge, this study is the first report on
reduced expression of CASP8 in breast cancer versus adjacent nor-
mal tissues. Since the induction of CASP8 expression – as a way to
sensitise tumour cells to apoptotic stimuli – had been done suc-
cessfully, this induction can be regarded as a new therapeutic
approach in this type of cancer as well [19]. More studies are cur-
rently being done on these samples to assess CASP8 protein expres-
sion and its relation with the genetic background of the population.
Evaluation of the outcome of expression reduction of this gene in
the apoptosis process and studying the mechanism of this reduc-
tion are also necessary to elucidate the potential role of this gene
in therapeutic measurements.
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